AstraZeneca inks more R&D collaborations; GSK races to FDA with melanoma combo; Acorda inks $8M deal;

@FierceBiotech: 'Fraud' found at China site for key study of Pfizer and Bristol's Eliquis. Report | Follow @FierceBiotech

 @JohnCFierce: Amgen commits $50M-plus in 3-way deal to expand cardiovascular drug pipeline. Article | Follow @JohnCFierce

@RyanMFierce: Expert exposes "highly questionable" data from biotech Cardio3 after IPO. ICYMI yesterday | Follow @RyanMFierce

> AstraZeneca ($AZN) won't be moving into its new HQ and research complex in Cambridge for another three years, but it's already building early-stage research ties in the region in the transition period. The pharma giant announced new research pacts with the University of Cambridge and Cancer Research UK Cambridge Institute on a new combo treatment for prostate cancer that adds AZD2014 to the experimental olaparib. And several Cambridge groups will work collaboratively onm new therapies for pancreatic cancer. Story

> GlaxoSmithKline ($GSK) has raced to regulators with an application to sell a combination of dabrafenib and trametinib for melanoma. The Big Pharma company is using Phase I/II data rather than waiting for late-stage results, expecting that regulators will be warmly receptive to early-stage data from a match of two drugs which are approved separately. Story

> Acorda ($ACOR) has nabbed two neuropathic pain therapies from NeurogesX ($NGSK): Qutenza and NP-1998. Qutenza is approved for neuropathic pain associated with postherpetic neuralgia while NP-1998 is a Phase III-ready capsaicin topical solution. Acorda paid about $8 million in the deal. Release

> Omthera Pharmaceuticals ($OMTH), which is being acquired by AstraZeneca ($AZN), has filed its NDA for the omega-3 drug Epanova. Release

Medical Device News

@FierceMedDev: New special report: A look at 2013's hot M&A start. Feature | Follow @FierceMedDev

 @MarkHFierce: It's not easy for Dx outfits to win Medicare coverage in today's market, but Crescendo did. Story | Follow @MarkHFierce

@DamianFierce: Are Intuitive's weak da Vinci sales a hiccup or an omen? Shares slipped 15% overnight. News | Follow @DamianFierce

> Diagnostic device detects bladder cancer through urine odor. Article

> Tyrx gains FDA clearance for dissolvable antibacterial envelope. Story

> Denmark wants EU ban on chemical used in device manufacturing. More

Pharma News

@FiercePharma: Investors hiss at Pharmstandard spinoff engineering. Plans to buy out investors who oppose OTC deal--at a discount. More | Follow @FiercePharma

 @CarlyHFierce: Alleged Botox marketing strategy in China named for Russian sniper Vasily Zaytsev - anyone seen Enemy at the Gates? More (sub. req.) | Follow @CarlyHFierce

> If Allergan went on the block, would Big Pharma bite? More

> Mylan's $1.6B Agila buyout hits snag in India amid cancer drug worries. Report

> Alzheimer's group pledges fight for Lilly's Amyvid. Article

Pharma Manufacturing News

 @EricPFierce: I'm looking for pharma folks interested in being part of a webinar on how their companies are using marketing apps to talk with clients. Let me know. | Follow @EricPFierce

> Nikkei: Teva to double manufacturing capacity in Japan. More

> Wockhardt faces 2nd import alert. Report

> Hikma New Jersey plant back in production. Article

> Fresenius gets 2nd warning letter in 18 months. Story

Biotech Research News

 @EmilyMFierce: Ohio-based startup Biosortia is tapping into nature to fill early drug-discovery void. Editor's corner | Follow @EmilyMFierce

> U.K. launches large-scale genomics project. More

> Immune modulation could explain how experimental Alzheimer's therapy works. Item

> More positive preclinical results for Inovio's H7N9 vaccine. Story

> New research could help cut cardiovascular risks associated with arthritis drugs. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.